Quelle

Davies M. et al., Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial, „Lancet” 2021, 397(10278), 971–984.
FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014, fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014 (21.07.2021).
Jarząb B., Płaczkiewicz-Jankowska E., Zespół mnogich nowotworów układu wydzielania wewnętrznego typu 2 (MEN2), www.mp.pl/interna/chapter/B16.II.12.2.2.2 (21.07.2021).
Rubino D. et al., Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial, „JAMA” 2021, 325(14), 1414–1425.
Wadden T.A. et al., Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial, „JAMA” 2021, 325(14), 1403–1413.
Wilding J.P.H. et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity, „New England Journal of Medicine” 2021, 384(11), 989.